TL;DR: August 2026's research brings reassurance on several fronts. A landmark 262-trial meta-analysis confirms that GLP-1 medications significantly reduce cardiovascular risk. The eye-safety scare is mostly a myth — randomised trial data shows lower rates of serious eye events in GLP-1 users than placebo. Lean mass loss is real but preventable with protein and resistance training. Most patients see their mood and sleep improve on treatment. Hair loss is nutritional, not toxic, and manageable. And for the first time, science is taking structured discontinuation seriously — the REST trial is now testing a gradual tapering approach. These are tools that work when used well.
Featured Finding: The Largest Drug Comparison in History — and What It Means for You
A network meta-analysis published in the BMJ in July 2026 compared 262 randomised controlled trials involving nearly 100,000 participants — making it the most comprehensive GLP-1 drug comparison ever conducted. The results clarify something patients have been wondering about for years: which medication actually works better?
At one year, compared to lifestyle change alone:
The headline: Tirzepatide wins on weight loss. Semaglutide wins on heart outcomes. Subcutaneous semaglutide is the only drug in this analysis associated with reduced all-cause mortality (risk reduced by 19%), reduced heart attacks (risk reduced by 28%), and reduced heart failure hospitalisation (risk reduced by 57%). Tirzepatide also reduced heart failure risk significantly.
This is not a reason to switch medications without a clinical conversation — it's evidence that both drugs are genuinely heart-protective, and the choice depends on individual circumstances. See our comparison guide for more context.
Source: Nong K et al., BMJ 2026;394:e372161. PMID 42419792. 262 RCTs, 99,791 participants.
Weight Maintenance & Lean Mass: What the August Data Actually Shows
The uncomfortable truth — and the hopeful solution
One of the most common patient concerns is muscle loss. The August 2026 evidence confirms it's real — and also confirms it's largely preventable.
A systematic review from the Baker Heart and Diabetes Institute (Alexander & Howden, Curr Opin Clin Nutr Metab Care, PMID 42130328) found that a portion of weight lost on GLP-1 medications may include lean tissue. This is not unique to these medications — any significant caloric restriction leads to some lean mass loss. The key question is how much, and whether it can be mitigated.
The answer from August 2026 research is encouraging:
- A TNO Netherlands study (Inia et al., Diabetes Metab J, PMID 42449565) found that adding exercise to semaglutide treatment preserved lean mass significantly better than semaglutide alone — while achieving greater fat mass reduction. Exercise activates molecular pathways that the medication simply cannot.
- A 12-month clinical programme combining tirzepatide with resistance training, testosterone support where indicated, protein counselling, and weekly check-ins showed patients losing an average of 20% body weight while actually increasing skeletal muscle mass by 4–12% — and gaining grip strength (Mendias & Awan, Obes Pillars, PMID 42620560).
- Animal research from the University of Alberta (Abuetabh et al., JCI Insight, PMID 42262870) found that ketone ester supplementation substantially blunted muscle loss from semaglutide. This is early-stage research, but the signal is promising.
The practical message: Lean mass loss is not a fixed side effect — it's a gap between what the medication does and what your body needs. Close that gap with resistance exercise two to three times per week and adequate protein (at least 1.2–1.6 g per kg of your goal body weight daily). Our exercise and maintenance guide explains how.
What happens when you stop — and weight cycling risk
The same Australian review found that more than half of GLP-1 medication users discontinue and restart within two years — a pattern called "weight cycling." The concerning finding: when patients stop and restart repeatedly, their body composition may worsen beyond where they started, as the weight that returns is predominantly fat rather than muscle.
This is not meant to frighten anyone into staying on medication indefinitely. It is meant to underscore that stopping should be a planned, supported decision — not a response to cost pressure, side-effect frustration, or a good week on the scale. Read our guide on planning a safe stop.
Side Effects & Safety — What's Real, What's Hype
Eye safety: the reassuring truth
Perhaps the most anxiety-generating headline of the past year has been the suggestion that GLP-1 medications cause a serious eye condition called NAION (non-arteritic anterior ischaemic optic neuropathy), which can cause sudden vision loss.
August 2026 research substantially clarifies this picture — and the news is mostly reassuring.
A large multi-centre study (Robertson et al., Ophthalmology, PMID 42556433) examining 2,169 NAION patients found that the key risk factor is not GLP-1 medication — it is a pre-existing anatomical feature called a "crowded optic disc" (a small optic nerve head with little surrounding space). People with this anatomy have 46 times greater odds of developing NAION, regardless of whether they take GLP-1 medications.
More importantly: a large Novo Nordisk-sponsored analysis of randomised controlled trial data (Vilsbøll et al., Br J Ophthalmol, PMID 42049287) covering 96,829 participants found that NAION rates were actually lower in GLP-1-treated patients than in those receiving placebo (approximately 3 cases per 100,000 person-years vs. 6 in placebo). In controlled trial data, the drug does not appear to cause more eye events — it may cause fewer.
Practical advice: If you have pre-existing eye conditions or notice any sudden vision changes, report them immediately. Stay well hydrated — one proposed mechanism involves dehydration amplifying risk in anatomically predisposed individuals. But for the vast majority of patients, the evidence does not support eye-related anxiety about these medications. Read our dedicated eye safety article.
Hair loss: it's nutritional, not toxic
Hair loss is real — a systematic review and meta-analysis of 17 studies covering over 1 million patient-exposures (Viquez Burboa et al., Skin Appendage Disord, PMID 42621629) confirmed a 40% increased risk of non-scarring hair loss with GLP-1 medications. But the mechanism matters enormously.
The research consistently points to telogen effluvium — a temporary hair-thinning condition triggered by nutritional deficiency during rapid weight loss — rather than any direct toxic effect of the medication on hair follicles. In other words, the medication is creating a caloric deficit, and if that deficit is poorly managed nutritionally, hair suffers.
What to do: Prioritise protein, zinc, iron, and biotin. The same protein targets that protect muscle also protect hair. In most cases, the shedding is temporary. Do not stop medication for hair loss alone without first discussing it with your clinical team. See our full hair loss guide.
Gastrointestinal symptoms — and the hydration gap
Nausea, vomiting, constipation, and diarrhoea remain the most common side effects, affecting 15–45% of patients for nausea and 5–30% for the others, depending on dose and individual tolerance. Slow dose titration, small frequent meals, avoiding fatty or spicy foods, and adequate hydration manage most cases.
What gets less attention is hydration. GLP-1 medications suppress not just appetite but thirst. Many patients significantly under-drink — which compounds constipation, fatigue, headaches, and may even contribute to the eye-safety signal described above. Aim for at least 2–2.5 litres of water daily and set reminders if needed. Read more about managing eating and drinking on treatment.
Mental Health Benefits: A Positive Note
The conversation about GLP-1 medications and mental health has focused heavily on rare negative signals. The August 2026 evidence rebalances this significantly.
A prospective Turkish study (Kır et al., J Endocrinol Invest, PMID 42611111) followed 78 patients on tirzepatide or semaglutide and measured depression scores (PHQ-9) and sleep quality before and during treatment. The results were striking:
- Median depression scores fell from 10 (moderate) to 6 (mild) — a clinically meaningful change
- The proportion of patients with clinically significant depression dropped from 55% to just 11.5%
- Sleep quality improved significantly, with poor sleep prevalence falling from 55% to 17%
Importantly, the improvements were not fully explained by weight loss alone — baseline depression severity predicted improvement independently. This suggests GLP-1 medications may have direct neurological effects that benefit mood and sleep.
A comprehensive Bradford Hill causality analysis of GLP-1 medications and neuropsychiatric outcomes (Schifano et al., Curr Psychiatry Rep, PMID 42624955) concluded that current evidence does not establish causality for negative psychiatric outcomes in the majority of patients. The biological plausibility exists — GLP-1 receptors are present in the brain — but the overwhelming real-world experience appears to be positive for mood.
One nuance to be aware of: a small case series (Nadolsky et al., Obes Pillars, PMID 42518361) documented three women at the highest dose of tirzepatide (15 mg/week) who experienced reduced motivation and emotional "flatness." In two of the three, lowering the dose to 10 mg resolved the symptoms. This is a signal worth monitoring at maximum doses — not a reason to avoid treatment, but a reason to have open conversations with your clinical team about how you're feeling emotionally at high doses.
Discontinuation & Anxiety: What the Science Says
The REST trial — a landmark study in how to stop
For the first time, the scientific community is formally studying how to discontinue GLP-1 medications rather than simply documenting that stopping leads to regain. The REST trial (Yevusiak et al., PLoS One, PMID 42507673), led by Mount Sinai and the University of Toronto, is testing whether a gradual 16-week dose reduction produces less weight regain than immediate cessation.
Results are not expected until 2027 — but the fact that this trial exists signals a meaningful shift. The clinical community now takes structured tapering seriously as a real strategy, not an optional nicety. Until results are available, our safe-stopping guide summarises what we know.
What actually happens when you stop
The honest picture: weight regain after stopping GLP-1 medications is significant and usually occurs within about one year. The Australian review (Alexander & Howden, PMID 42130328) found near-complete reversal of both weight loss and cardiometabolic improvements within roughly 12 months of abrupt cessation.
This does not mean it is pointless to stop — it means that stopping without lifestyle infrastructure in place is a high-risk decision. The "food noise" reduction that patients describe as transformative (documented in the JAMA Network Open qualitative study, de Vere Hunt et al., PMID 42247231) reverses with medication clearance, typically within days to weeks.
Conservative framing: Regain can be rapid, with most individuals regaining significant weight within one year of stopping treatment. This is why GLP-1 medications are increasingly understood as chronic disease management tools for selected patients — similar to blood pressure medication, not a short course of antibiotics.
"Is this forever?" — addressing the dependency concern
Many patients worry they are becoming "dependent" or "addicted" to these medications. The evidence is clear: GLP-1 medications are not physiologically addictive in the way that, for example, opioids are. There is no tolerance requiring escalating doses for the same effect, and no classic physical withdrawal syndrome.
What there is: obesity is a chronic condition. When medication is stopped, the condition typically returns — just as blood pressure returns when antihypertensives are stopped. This is disease management, not dependency. The decision about duration belongs in a clinical conversation, not in headlines.
Emerging August 2026 Research
Tirzepatide vs. semaglutide in the real world
A Chinese real-world study of 183 patients (Yao et al., Diabetes Metab Syndr Obes, PMID 42610030) confirmed that tirzepatide produces greater weight loss (about 2.9 kg more) and a higher proportion of patients achieving 10% weight loss. Appetite regulation was comparable between the two drugs. This aligns with the BMJ network meta-analysis and gives real-world support to the clinical impression that tirzepatide is the stronger weight-loss agent.
The next generation of medications
The BMJ meta-analysis also evaluated emerging agents. CagriSema (cagrilintide plus semaglutide) achieved results comparable to tirzepatide (−14.8% at one year) and is in Phase 3 trials. Oral non-peptide GLP-1 medications (orforglipron, HRS-7535) are progressing through trials and may eventually offer injection-free options. Triple agonists targeting three receptor types simultaneously (retatrutide) show early promise for greater than 20% weight loss, though evidence quality remains low.
GLP-1 medications beyond weight
August 2026 research continued to expand the scope of what GLP-1 medications appear to treat. Significant benefits are documented or under investigation for sleep apnoea, metabolic liver disease (MASH), cognitive protection in diabetes, idiopathic intracranial hypertension, and kidney protection. These are not reasons to seek these medications outside their approved uses — but they do reinforce that the mechanism of action is broad and the long-term benefits may extend well beyond the scale.
Protein adequacy in older patients
A University of Liverpool/University of Florida study (Prokopidis et al., Adv Ther, PMID 42631799) raised an important point for patients over 60: even when protein proportion of the diet is maintained during GLP-1 treatment, total protein intake falls because calories fall overall. In older adults, who are already at risk for muscle loss (sarcopenia), this gap requires active dietary management and monitoring. If you are over 60 and on GLP-1 treatment, protein targets and functional strength monitoring should be explicit parts of your plan.
Key Takeaways for Élan Patients
1. Your heart is better protected than you might think. Both semaglutide and tirzepatide reduce cardiovascular risk significantly. The evidence is strong and consistent. (PMID 42419792)
2. Eye safety concerns are mostly a myth for most patients. Randomised trial data shows lower eye event rates in GLP-1 users than placebo. The risk is concentrated in people with a specific pre-existing anatomical variant. Stay hydrated. Report any sudden vision changes. (PMID 42049287, 42556433)
3. Lean mass loss is real but preventable. With resistance training 2–3x per week and ≥1.2 g protein per kg body weight daily, you can substantially protect your muscle — and may even gain it. (PMID 42620560, 42449565)
4. Most patients feel better emotionally on treatment, not worse. Depression scores improve significantly in prospective data. If you feel emotionally flat at the maximum dose, mention it to your team — dose adjustment often resolves it. (PMID 42611111, 42518361)
5. Hair loss is manageable and usually temporary. It is a nutritional gap, not drug toxicity. Protein, zinc, iron, and biotin are the interventions. (PMID 42621629)
6. If you're thinking about stopping, plan it carefully. The REST trial represents the field finally taking structured discontinuation seriously. Until results are available, plan any stop with your clinical team — not alone, and not in response to a difficult week. (PMID 42507673)
Related reading
Primary Sources (Selected)
Frequently Asked Questions
Do GLP-1 medications really cause eye problems?
The short answer is: not according to randomised controlled trial data. A large analysis of trial data covering nearly 97,000 participants found that rates of NAION (the eye condition cited in media reports) were actually lower in patients receiving GLP-1 medications than in those receiving placebo — approximately 3 cases per 100,000 person-years vs. 6 in placebo (Vilsbøll et al., Br J Ophthalmol, PMID 42049287).
The risk appears to be concentrated in people with a pre-existing anatomical feature (a "crowded optic disc") who are also poorly hydrated. For most patients, there is no evidence of increased eye risk. Report any sudden vision changes immediately and stay well hydrated.
Will I lose muscle mass on Wegovy or Mounjaro?
Some lean mass loss can occur during any period of significant caloric restriction — and GLP-1 medications create caloric restriction by reducing appetite. However, the August 2026 evidence is clear that this is substantially preventable. Resistance exercise and adequate protein intake (at least 1.2 g per kg of body weight daily) protect lean mass and may even allow muscle gain during treatment. One 12-month programme combining tirzepatide with resistance training showed skeletal muscle mass increasing by 4–12% while total weight fell by 20% (PMID 42620560). The key is active effort — the medication does not protect muscle automatically.
Does hair loss from GLP-1 medications grow back?
In most cases, yes. The primary cause is telogen effluvium — a temporary shedding phase triggered by nutritional stress during rapid weight loss, not direct drug toxicity. Once nutrition is optimised (particularly protein, zinc, iron, and biotin) and the rate of weight loss stabilises, most patients see regrowth. A large meta-analysis (PMID 42621629) confirmed the elevated risk but also confirmed the mechanism is nutritional. Do not stop medication for hair loss alone without a clinical conversation first.
What happens to my mood on GLP-1 medications?
For the majority of patients, mood improves. A prospective study (Kır et al., PMID 42611111) found that depression scores dropped significantly and sleep quality improved meaningfully in patients on semaglutide and tirzepatide. The proportion of patients with clinically significant depression fell from 55% to 11.5%. A small minority of patients at the highest tirzepatide dose reported feeling emotionally flat — this resolved with dose reduction in most cases. Tell your clinical team if you notice emotional changes at any point in treatment.
What happens if I stop taking my GLP-1 medication?
Weight typically begins returning, and most of the cardiometabolic improvements (blood pressure, blood fats, insulin sensitivity) reverse as weight is regained. Research suggests that most of the regain occurs within about one year of abrupt cessation. Importantly, the weight that returns is predominantly fat rather than muscle — meaning body composition can be worse than before treatment if muscle was not actively protected during the treatment period. Structured, planned stopping with lifestyle support in place is far better than abrupt cessation. The REST trial is currently testing whether gradual tapering reduces regain (PMID 42507673) — results expected 2027.
Are these medications addictive?
No — not in the physiological sense. GLP-1 medications do not create tolerance (where you need more for the same effect) and do not cause physical withdrawal symptoms. The concern patients describe is really about chronic disease management: obesity is a lifelong condition, and stopping medication typically allows the condition to return — just as stopping blood pressure medication allows blood pressure to rise. This is disease recurrence, not addiction. The decision about how long to remain on treatment is a clinical one, not a moral judgement.
Evidence should guide your plan, not your anxiety
Élan translates the latest obesity-medicine evidence into individual care plans — covering medication, nutrition, exercise, and long-term maintenance. Book a consultation to talk through what the August research means for your specific situation.
Book a consultation